Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 18

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 18
---
 carefully                                          
 consider before deciding to invest in our securities.                                                                                                                             |
| Nasdaq                                             
 listing symbol                                     |     | Our                                                                                                                                                                               
 Common Stock is listed on the Nasdaq Capital Market under the symbol “BIAF”. There is no established trading market for                                                           
 the May 2025 Warrants or the Pre-Funded Warrants and we do not expect a market to develop. In addition, we do not intend to                                                       
 apply for the listing of the May 2025 Warrants or Pre-Funded Warrants on any national securities exchange or other trading                                                        
 market. Without an active trading market, the liquidity of the May 2025 Warrants and Pre-Funded Warrants will be limited.                                                         |
| Transfer Agent and Warrant Agent                   |     | The transfer agent and registrar for our Common Stock and                                                                                                                         
 the Warrant Agent for the May 2025 Warrants is VStock Transfer, LLC.                                                                                                              |

The information above is based on 18,246,331 shares of Common Stock outstanding as of April 25, 2025, and excludes, as of that date the following:

| ● | 12,873,602                                                                                
 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted 
 average exercise price equal to $2.74 per share;                                          |

| ● | 304,125                                                                                    
 shares of Common Stock issuable upon the exercise of stock options issued under our equity 
 incentive plans with a weighted average exercise price equal to $6.95 per share; and       |

| ● | 1,249,024                                                                                  
 shares                                                                                     
 of our Common Stock that are reserved for equity awards that may be granted under our 2024 
 Equity Incentive Plan.                                                                     |

Unless otherwise indicated, all information contained in this prospectus assumes:

| ● | no                                                                                             
 exercise of the outstanding options, warrants, or pre-funded warrants described in the bullets 
 above;                                                                                         |

| ● | no                                                                                         
 exercise of the May 2025 Warrants or the Placement Agent Warrants issued in this offering; 
 and                                                                                        |

| ● | no                                            
 sale of Pre-Funded Warrants in this offering. |

| 5 |

<div align='center'>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

Certain statements in this prospectus may contain “forward-looking statements” within the meaning of the federal securities laws. Our forward-looking statements include, but are not limited to, statements about us and our